+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Thrombosis Drug Market by Route of Administration, End User, Treatment Type, Drug Class, Indication - Global Forecast to 2030- Product Image
Thrombosis Drug Market by Route of Administration, End User, Treatment Type, Drug Class, Indication - Global Forecast to 2030- Product Image
Sale

Thrombosis Drug Market by Route of Administration, End User, Treatment Type, Drug Class, Indication - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6084177
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Thrombosis Drug Market grew from USD 30.60 billion in 2024 to USD 32.48 billion in 2025. It is expected to continue growing at a CAGR of 5.86%, reaching USD 43.09 billion by 2030.

Setting the Stage for Thrombosis Drug Market Insights

Thrombosis continues to exert a profound impact on global health systems, driving significant clinical and economic burdens across patient populations. The formation of blood clots in veins or arteries can lead to life-threatening events such as stroke, pulmonary embolism, and deep vein thrombosis, underscoring the critical need for effective preventive and therapeutic options. As the population ages and comorbidities such as diabetes and obesity rise, incidence rates are projected to remain elevated, placing sustained pressure on healthcare infrastructures and budgets.

Recent advances have expanded the armamentarium of antithrombotic agents, moving beyond traditional vitamin K antagonists to include targeted direct oral anticoagulants, low molecular weight heparins, and antiplatelet combinations. This diversification of treatments has been matched by growing emphasis on personalized medicine, patient adherence solutions, and value-based care models. Payers and providers alike are seeking data-driven insights to justify drug adoption, optimize treatment protocols, and improve long-term outcomes.

This executive summary presents a structured overview of the current thrombosis drug landscape, spotlighting transformative market dynamics, tariff implications, segmentation nuances, regional trends, and key competitive maneuvers. By weaving together these critical dimensions, industry leaders can forge robust strategies that address evolving patient needs and regulatory environments.

Emerging Paradigms Reshaping Thrombosis Therapy

A confluence of technological breakthroughs and shifting clinical paradigms is reshaping the thrombosis treatment landscape. Precision diagnostics leveraging artificial intelligence now enable earlier and more accurate risk stratification, allowing clinicians to tailor prophylactic regimens to individual patient profiles. Simultaneously, digital health solutions-from remote monitoring wearables to mobile adherence applications-are enhancing patient engagement and reducing the incidence of adverse events.

On the therapeutic front, novel mechanisms of action are emerging. Factor XI inhibitors and RNA-based therapeutics are transitioning from clinical trials to late-stage development, promising to fill unmet needs in patients who exhibit resistance or intolerance to existing options. Biosimilar introductions and strategic licensing partnerships are also intensifying competition, driving down costs and expanding access in markets that historically grappled with budgetary constraints.

In parallel, value-based contracting models are gaining traction, as payers demand evidence of real-world effectiveness and long-term economic benefits. These developments are catalyzing collaborations across industry stakeholders, from biotech innovators to health systems, fostering an ecosystem committed to delivering safer, more cost-efficient thrombosis care.

Navigating Tariff-Driven Forces in US Thrombosis Therapies

The implementation of United States tariffs on active pharmaceutical ingredients and finished formulations in 2025 has introduced a complex layer of commercial considerations for thrombosis drug manufacturers. Import duties on key raw materials have led to elevated production costs, particularly for injectable biologics and high-purity small molecule anticoagulants. Manufacturers are reevaluating supply chain configurations, exploring near-shoring and dual-sourcing strategies to mitigate exposure to tariff volatility and maintain cost-competitive pricing structures.

Distribution channels have also adjusted to accommodate these new cost pressures. Wholesale distributors and hospital procurement teams are negotiating revised pricing agreements, while smaller retail pharmacies face tighter margins amid rising acquisition expenses. These shifts have prompted early discussions around value-based pricing frameworks that align reimbursement with clinical performance metrics, helping stakeholders share both risks and rewards more equitably.

Despite these headwinds, the tariff landscape has spurred innovation in process efficiencies. Contract development and manufacturing organizations are investing in continuous manufacturing technologies and green chemistry practices to reduce dependence on imported intermediates. As a result, the industry is poised to emerge more resilient and agile, equipped to navigate future policy shifts.

Unveiling Core Segments Driving Treatment Modalities

Dissecting the thrombosis drug market through a segmentation lens reveals the nuanced interplay of treatment modalities and delivery channels. Administration preferences split between injectable formats-encompassing both intravenous infusion and subcutaneous injection-and oral dosage forms, which include capsule and tablet presentations. This duality influences not only clinical adoption but also patient convenience and adherence, as outpatient care models increasingly favor self-administration and minimized clinic visits.

End user segmentation further delineates the market between hospital settings and retail pharmacies. Inpatient environments drive demand for high-intensity acute therapies, while community pharmacies serve as critical touchpoints for chronic management and follow-up. Within the broader therapeutic landscape, the prophylaxis segment bifurcates into medical and surgical prophylaxis, addressing both ambulatory patient needs and peri-operative risk mitigation. On the therapeutic side, acute interventions target immediate clot dissolution, whereas long-term maintenance regimens focus on preventing recurrence and ensuring sustained anticoagulant effects.

Drug class stratification underscores the diversity of available agents. Antiplatelet therapies, led by options such as aspirin and clopidogrel, remain foundational for certain patient cohorts, while direct oral anticoagulants have surged ahead through distinct subclasses of direct thrombin inhibitors like dabigatran and factor Xa inhibitors including apixaban, betrixaban, edoxaban, and rivaroxaban. The low molecular weight heparin category, featuring dalteparin, enoxaparin, and tinzaparin, retains prominence for inpatient prophylaxis, alongside unfractionated heparins. Vitamin K antagonists, most notably warfarin, continue to play a role where monitoring infrastructure supports regular INR assessments. Indication-based segmentation spans atrial fibrillation, deep vein thrombosis, and pulmonary embolism, each demanding tailored therapeutic strategies and monitoring protocols.

Regional Dynamics Steering Thrombosis Care Trends

Regional dynamics exert a powerful influence on how thrombosis treatments are accessed, reimbursed, and delivered. In the Americas, established healthcare infrastructure and robust reimbursement mechanisms support early adoption of innovative therapies, though payer scrutiny and formulary negotiations can lengthen market access timelines. Patient advocacy and real-world registry data generation in this region often serve as launchpads for new value-based contracting models.

Across Europe, the Middle East, and Africa, heterogeneity in regulatory frameworks and healthcare spending yields a fragmented yet opportunity-rich environment. Western European markets exhibit high penetration of direct oral anticoagulants, driven by streamlined approval pathways and comprehensive reimbursement. In contrast, emerging economies face budgetary limitations that sustain demand for cost-effective generics and biosimilars. Collaborative initiatives between public and private sectors are increasingly deployed to expand access and improve continuity of care in underserved areas.

The Asia-Pacific region stands out for its rapid regulatory evolution and growing investment in domestic biopharmaceutical capabilities. Markets such as Japan and Australia demonstrate swift uptake of next-generation anticoagulants, while greater China and Southeast Asian nations present large patient pools coupled with expanding healthcare budgets. Local manufacturers are partnering with global innovators to co-develop and commercialize tailored formulations, further intensifying competition and driving down treatment costs.

Competitive Landscape and Leading Innovators in Antithrombotic Space

Competitive pressures in the thrombosis drug market are shaped by both established pharmaceutical giants and agile biotech challengers. Leading incumbents have fortified their portfolios through strategic acquisitions and collaborative R&D partnerships, accelerating the development of next-generation anticoagulants and antidote therapies. Key players are also leveraging expansive distribution networks and patient support services to enhance market reach and foster long-term brand loyalty.

Biotech innovators are carving out niches with highly targeted molecular entities and novel delivery platforms that promise differentiated safety and efficacy profiles. These entrants are often backed by venture capital and specialty investors, enabling rapid progression from clinical proof of concept to late-stage studies. Their agility in trial design and regulatory engagement challenges traditional commercialization models, compelling larger firms to adopt more flexible development pathways.

Generic and biosimilar manufacturers are intensifying competition by offering cost-effective alternatives to branded therapies. Their growing capabilities in biologics manufacturing, coupled with regulatory incentives for biosimilar adoption, are reshaping procurement strategies across both hospital and retail channels. As a result, originator companies must demonstrate clear clinical advantages and invest in value demonstration studies to preserve market share against these high-volume, low-cost competitors.

Strategic Pathways to Enhance Market Position in Thrombosis Care

Industry leaders can capitalize on shifting market dynamics by embracing several strategic imperatives. First, optimizing supply chain resilience through regional diversification and advanced manufacturing technologies will mitigate tariff-related cost pressures and ensure continuity of supply. Close collaboration with contract manufacturers and the adoption of continuous processing can yield both quality improvements and operational efficiencies.

Second, forging partnerships with digital health platform providers will enhance patient adherence and real-world evidence collection, bolstering value propositions with payers. Integrating telemonitoring tools and mobile applications into post-discharge protocols can reduce hospital readmissions and drive measurable improvements in long-term outcomes.

Third, investing in differentiated clinical development programs-such as factor XI inhibitors or targeted reversal agents-can create high-barrier assets that support premium pricing and extended exclusivity. Concurrently, engaging proactively with health technology assessment bodies will facilitate smoother access pathways and strengthen reimbursement dossiers. Together, these strategies will position companies to lead in both established and emerging markets.

Rigorous Approach Underpinning Market Analysis

This analysis is underpinned by a rigorous mixed-methods research framework. Primary data was collected through in-depth interviews with key opinion leaders, hospital pharmacists, payers, and clinical trial investigators across major markets. These qualitative insights were triangulated with quantitative data derived from industry publications, regulatory filings, and proprietary databases to ensure comprehensive coverage and validity.

Secondary research encompassed a systematic review of peer-reviewed journals, conference proceedings, company reports, and government policy documents. Advanced data modeling techniques were employed to analyze supply chain cost structures, tariff impacts, and competitive landscapes. Throughout the research process, findings were subjected to multi-layered peer review and expert validation to deliver an authoritative and actionable market perspective.

Synthesizing Insights for Future-Thinking Stakeholders

In synthesizing these insights, it becomes clear that the thrombosis drug market is at an inflection point, driven by technological innovation, regulatory evolution, and shifting payer paradigms. The interplay of tariff pressures, segmentation complexities, and regional heterogeneity underscores the need for dynamic strategies that balance cost management with clinical differentiation.

Stakeholders who adopt agile supply chain configurations, invest in value-demonstrating real-world evidence, and pursue strategic collaborations will be best positioned to navigate this evolving landscape. The convergence of next-generation therapeutics and digital health solutions offers unprecedented opportunities to enhance patient outcomes and create sustainable commercial advantages.

Ultimately, the organizations that align their product development, market access, and commercialization efforts around these core imperatives will lead the next chapter of thrombosis care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Injectable
      • Intravenous
      • Subcutaneous
    • Oral
      • Capsule
      • Tablet
  • End User
    • Hospital
    • Retail Pharmacy
  • Treatment Type
    • Prophylaxis
      • Medical Prophylaxis
      • Surgical Prophylaxis
    • Therapeutic
      • Acute Therapy
      • Long Term Therapy
  • Drug Class
    • Antiplatelet Agents
      • Aspirin
      • Clopidogrel
    • Direct Oral Anticoagulants
      • Direct Thrombin Inhibitors
        • Dabigatran
      • Factor Xa Inhibitors
        • Apixaban
        • Betrixaban
        • Edoxaban
        • Rivaroxaban
    • Low Molecular Weight Heparins
      • Dalteparin
      • Enoxaparin
      • Tinzaparin
    • Unfractionated Heparins
    • Vitamin K Antagonists
      • Warfarin
  • Indication
    • Atrial Fibrillation
    • Deep Vein Thrombosis
    • Pulmonary Embolism
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Boehringer Ingelheim GmbH
  • Sanofi S.A.
  • Daiichi Sankyo Company, Limited
  • Leo Pharma A/S

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Thrombosis Drug Market, by Route of Administration
8.1. Introduction
8.2. Injectable
8.2.1. Intravenous
8.2.2. Subcutaneous
8.3. Oral
8.3.1. Capsule
8.3.2. Tablet
9. Thrombosis Drug Market, by End User
9.1. Introduction
9.2. Hospital
9.3. Retail Pharmacy
10. Thrombosis Drug Market, by Treatment Type
10.1. Introduction
10.2. Prophylaxis
10.2.1. Medical Prophylaxis
10.2.2. Surgical Prophylaxis
10.3. Therapeutic
10.3.1. Acute Therapy
10.3.2. Long Term Therapy
11. Thrombosis Drug Market, by Drug Class
11.1. Introduction
11.2. Antiplatelet Agents
11.2.1. Aspirin
11.2.2. Clopidogrel
11.3. Direct Oral Anticoagulants
11.3.1. Direct Thrombin Inhibitors
11.3.1.1. Dabigatran
11.3.2. Factor Xa Inhibitors
11.3.2.1. Apixaban
11.3.2.2. Betrixaban
11.3.2.3. Edoxaban
11.3.2.4. Rivaroxaban
11.4. Low Molecular Weight Heparins
11.4.1. Dalteparin
11.4.2. Enoxaparin
11.4.3. Tinzaparin
11.5. Unfractionated Heparins
11.6. Vitamin K Antagonists
11.6.1. Warfarin
12. Thrombosis Drug Market, by Indication
12.1. Introduction
12.2. Atrial Fibrillation
12.3. Deep Vein Thrombosis
12.4. Pulmonary Embolism
13. Americas Thrombosis Drug Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Thrombosis Drug Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Thrombosis Drug Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bayer AG
16.3.2. Bristol-Myers Squibb Company
16.3.3. Pfizer Inc.
16.3.4. Boehringer Ingelheim GmbH
16.3.5. Sanofi S.A.
16.3.6. Daiichi Sankyo Company, Limited
16.3.7. Leo Pharma a/S
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. THROMBOSIS DRUG MARKET MULTI-CURRENCY
FIGURE 2. THROMBOSIS DRUG MARKET MULTI-LANGUAGE
FIGURE 3. THROMBOSIS DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. THROMBOSIS DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. THROMBOSIS DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. THROMBOSIS DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY MEDICAL PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ACUTE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LONG TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY APIXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY BETRIXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY EDOXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RIVAROXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DALTEPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ENOXAPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TINZAPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY UNFRACTIONATED HEPARINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY WARFARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 88. CANADA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. CANADA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 90. CANADA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 91. CANADA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. CANADA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. CANADA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 94. CANADA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 95. CANADA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. CANADA THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 97. CANADA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 98. CANADA THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. CANADA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. CANADA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 101. CANADA THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 102. CANADA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. MEXICO THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. MEXICO THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 106. MEXICO THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. MEXICO THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. MEXICO THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 110. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. MEXICO THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 117. MEXICO THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. GERMANY THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. GERMANY THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 181. GERMANY THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 182. GERMANY THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. GERMANY THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. GERMANY THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 186. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 188. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 189. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. GERMANY THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. GERMANY THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 192. GERMANY THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 193. GERMANY THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 194. FRANCE THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. FRANCE THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 196. FRANCE THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 197. FRANCE THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. FRANCE THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. FRANCE THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 200. FRANCE THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 201. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 202. FRANCE THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 203. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 204. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. FRANCE THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 206. FRANCE THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 207. FRANCE THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 208. FRANCE THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 218. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 219. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. ITALY THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. ITALY THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 226. ITALY THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 227. ITALY THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. ITALY THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 229. ITALY THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 230. ITALY THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 231. ITALY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. ITALY THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 233. ITALY THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 234. ITALY THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. ITALY THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. ITALY THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 237. ITALY THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 238. ITALY THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 239. SPAIN THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. SPAIN THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 241. SPAIN THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 242. SPAIN THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. SPAIN THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 244. SPAIN THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 245. SPAIN THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 246. SPAIN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. SPAIN THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 248. SPAIN THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 249. SPAIN THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. SPAIN THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. SPAIN THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 252. SPAIN THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 253. SPAIN THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 280. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 282. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 290. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 292. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 294. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 296. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 298. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 299. DENMARK THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. DENMARK THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 301. DENMARK THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 302. DENMARK THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. DENMARK THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 304. DENMARK THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 305. DENMARK THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 306. DENMARK THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 307. DENMARK THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 308. DENMARK THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 309. DENMARK THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 310. DENMARK THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 311. DENMARK THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 312. DENMARK THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 313. DENMARK THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 314. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 316. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 317. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 319. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 320. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 321. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 322. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 323. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 324. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 325. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 326. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 327. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 328. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 329. QATAR THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 330. QATAR THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 331. QATAR THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 332. QATAR THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 333. QATAR THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 334. QATAR THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 335. QATAR THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 336. QATAR THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 337. QATAR THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 338. QATAR THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 339. QATAR THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 340. QATAR THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 341. QATAR THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2030 (USD MILLION)
TABLE 342. QATAR THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 343. QATAR THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Thrombosis Drug market report include:
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Boehringer Ingelheim GmbH
  • Sanofi S.A.
  • Daiichi Sankyo Company, Limited
  • Leo Pharma A/S

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 32.48 Billion
Forecasted Market Value ( USD ) by 2030 $ 43.09 Billion
Compound Annual Growth Rate5.8%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Thrombosis Drugs - Global Strategic Business Report - Product Image

Thrombosis Drugs - Global Strategic Business Report

  • Report
  • 387 Pages
  • Global
From
Thrombosis Drugs Market 2024-2028 - Product Image

Thrombosis Drugs Market 2024-2028

  • Report
  • 144 Pages
  • Global
From
Arterial Thrombosis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Arterial Thrombosis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 81 Pages
  • Global
From
Heparin-induced Thrombocytopenia - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Heparin-induced Thrombocytopenia - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Chronic Venous Occlusions Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Chronic Venous Occlusions Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 120 Pages
  • Global
From

About the Thrombosis Drug Market

The Thrombosis Drug market is a subset of the Cardiovascular Drugs market, which focuses on the prevention and treatment of blood clots. Thrombosis drugs are used to reduce the risk of stroke, heart attack, and other cardiovascular events. These drugs work by preventing the formation of blood clots, or by dissolving existing clots. Commonly used thrombosis drugs include anticoagulants, antiplatelet agents, and thrombolytics. Anticoagulants, such as warfarin and heparin, are used to prevent the formation of blood clots. Antiplatelet agents, such as aspirin and clopidogrel, are used to prevent the formation of clots in the arteries. Thrombolytics, such as alteplase and streptokinase, are used to dissolve existing clots. Some companies in the Thrombosis Drug market include Bayer, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.